Prodrug of an ICE inhibitor

Patent metadata

Field	Value
Publication number	US-9994613-B2
Application number	US-201615288863-A
Country	US
Kind code	B2
Filing date	Oct 7, 2016
Priority date	May 19, 2000
Publication date	Jun 12, 2018
Grant date	Jun 12, 2018

Abstract

This invention describes an ICE inhibitor prodrug (I) having good bioavailability.

Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.

First claim

We claim:

1. A topical formulation comprising a compound of formula I, or a pharmaceutically acceptable salt thereof:

and a pharmaceutically acceptable carrier, adjuvant, or vehicle;
wherein the pharmaceutically acceptable carrier, adjuvant, or vehicle is a mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, water, or a combination thereof.

2. The topical formulation of claim 1 , wherein the topical formulation comprises a therapeutically effective amount of the compound of formula I, or the pharmaceutically acceptable salt thereof.

3. The topical formulation of claim 1 , wherein the topical formulation is an ointment.

4. The topical formulation of claim 1 , wherein the topical formulation is a cream or a lotion.

5. The topical formulation of claim 1 , wherein the compound of formula I, or pharmaceutically acceptable salt thereof, is in an amount of 5% w/w to 95% w/w of the topical formulation.

6. The topical formulation of claim 1 , further comprising an additional agent, wherein the additional agent is an anti-inflammatory agent, a matrix metalloprotease inhibitor, a lipoxygenase inhibitor, a cytokine antagonist, an immunosuppressant, an anti-cancer agent, an anti-viral agent, a cytokine, a growth factor, an immunomodulator, a prostaglandin, an anti-vascular hyperproliferation compound, a pharmaceutically acceptable adjuvant, or a combination thereof.

7. A topical formulation comprising a compound of formula I:

and a pharmaceutically acceptable carrier, adjuvant, or vehicle;
wherein the pharmaceutically acceptable carrier, adjuvant, or vehicle is a mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, water, or a combination thereof.

8. A topical formulation comprising a compound of formula I-A:

and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

9. A topical formulation comprising a compound of formula I-B:

and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

10. A method of treating a disease in a subject in need thereof, comprising the step of administering to said subject a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof:

and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein the disease is atopic dermatitis, acute dermatomyositis, eczema, metastatic melanoma, or a combination thereof.

11. The method of claim 10 , wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound of formula I, or the pharmaceutically acceptable salt thereof.

12. The method of claim 10 , wherein the pharmaceutical composition is administered one to five times a day.

13. The method of claim 10 , wherein the compound of formula I, or pharmaceutically acceptable salt thereof, is in an amount of 5% w/w to 95% w/w of the pharmaceutical composition.

14. The method of claim 10 , wherein the pharmaceutical composition is administered in combination with an additional agent, and wherein the additional agent is an anti-inflammatory agent, a matrix metalloprotease inhibitor, a lipoxygenase inhibitor, a cytokine antagonist, an immunosuppressant, an anti-cancer agent, an anti-viral agent, a cytokine, a growth factor, an immunomodulator, a prostaglandin, an anti-vascular hyperproliferation compound, a pharmaceutically acceptable adjuvant, or a combination thereof.

15. The method of claim 10 , wherein the pharmaceutical composition further comprises an additional agent, and wherein the additional agent is an anti-inflammatory agent, a matrix metalloprotease inhibitor, a lipoxygenase inhibitor, a cytokine antagonist, an immunosuppressant, an anti-cancer agent, an anti-viral agent, a cytokine, a growth factor, an immunomodulator, a prostaglandin, an anti-vascular hyperproliferation compound, a pharmaceutically acceptable adjuvant, or a combination thereof.

16. The method of claim 10 , wherein the pharmaceutical composition is a topical composition.

17. The method of claim 16 , wherein the topical composition is an ointment, a cream, or a lotion.

18. A method of treating a disease in a subject in need thereof, comprising the step of administering to said subject a pharmaceutical composition comprising a compound of formula I:

and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein the disease is atopic dermatitis, acute dermatomyositis, eczema, metastatic melanoma, or a combination thereof.

19. A method of treating atopic dermatitis in a subject in need thereof, comprising the step of administering to said subject a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof:

and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

20. The method of claim 19 , wherein the pharmaceutical composition comprises a therapeutically effective amount of the compound of formula I, or the pharmaceutically acceptable salt thereof.

21. The method of claim 19 , wherein the pharmaceutical composition is administered one to five times a day.

22. The method of claim 19 , wherein the compound of formula I, or pharmaceutically acceptable salt thereof, is in an amount of 5% w/w to 95% w/w of the pharmaceutical composition.

23. The method of claim 19 , wherein the pharmaceutical composition is a topical composition.

24. The method of claim 23 , wherein the topical composition is an ointment, a cream or a lotion.

25. The method of claim 19 , wherein the pharmaceutical composition is administered in combination with an additional agent, and wherein the additional agent is an anti-inflammatory agent, a matrix metalloprotease inhibitor, a lipoxygenase inhibitor, a cytokine antagonist, an immunosuppressant, an anti-cancer agent, an anti-viral agent, a cytokine, a growth factor, an immunomodulator, a prostaglandin, an anti-vascular hyperproliferation compound, a pharmaceutically acceptable adjuvant, or a combination thereof.

26. The method of claim 19 , wherein the pharmaceutical composition further comprises an additional agent, and wherein the additional agent is an anti-inflammatory agent, a matrix metalloprotease inhibitor, a lipoxygenase inhibitor, a cytokine antagonist, an immunosuppressant, an anti-cancer agent, an anti-viral agent, a cytokine, a growth factor, an immunomodulator, a prostaglandin, an anti-vasc

Assignees

• Vertex Pharma

Inventors

• Wannamaker Marion W
• Davies Robert J

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title